Is lurbinectedin safe for pregnant women?
No, lurbinectedin is not safe for pregnant women. It carries a boxed warning for embryo-fetal toxicity and is classified as pregnancy category D, indicating positive evidence of human fetal risk based on animal studies and limited human data. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the final dose. Animal reproduction studies showed developmental toxicity, including embryo-fetal death and malformations, at doses lower than human equivalents.[1][2]
What do animal studies show about fetal risks?
In rats and rabbits, lurbinectedin caused embryo-fetal lethality, reduced fetal weight, and skeletal/organ abnormalities at exposures below those in humans. No adequate human pregnancy studies exist due to the drug's oncology use, but the mechanism—DNA damage via transcription inhibition—suggests high teratogenic potential.[1][3]
Can pregnant women receive lurbinectedin for cancer treatment?
Avoid use in pregnancy unless benefits outweigh risks, with no alternatives. Verify pregnancy status before starting and counsel on contraception. If exposure occurs, assess fetal development via ultrasound; no specific antidote exists.[1][2]
What about male patients and fertility?
Lurbinectedin impairs male fertility in animals via testicular toxicity. Men should use condoms during treatment and for 4 months after, even if partners use contraception.[1]
How does this compare to other chemotherapy drugs?
Like platinum agents (e.g., cisplatin) or topoisomerase inhibitors, lurbinectedin is contraindicated in pregnancy due to genotoxicity. Unlike some hormonal therapies, it has no established safety profile in any trimester.[3]
[1]: Lurbinectedin ( Zepzelca) prescribing information, Jazz Pharmaceuticals
[2]: Drugs.com - Lurbinectedin use during pregnancy
[3]: FDA Oncology Center of Excellence - Drug safety in pregnancy